ClinicalTrials.gg
CompletedNCT02783599Updated Aug 12, 2019Results posted

A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

A Phase 1 interventional study of Olaratumab and Doxorubicin in Soft Tissue Sarcoma, sponsored by Eli Lilly and Company. Completed at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-12.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing doxorubicin in Sarcoma — 13 open to participants now, 14 under way, 2 of them phase 3. Doxorubicin · Sarcoma.

Enrollment
23rd of 60
51 · median 42
Started
2016
with 5 others
Phase 1
15 of 65
3 open now
Registered
44th of 65
by date
Lead sponsor
2 of 65
Eli Lilly and Company

Among the 65 studies testing doxorubicin in Sarcoma, this one is the 23rd largest by enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2016, is one of 15 in phase 1, and was the 44th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

13 of the 65 studies testing doxorubicin in Sarcoma are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About doxorubicin

Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 301 Sarcoma studies recruiting now, 191 (63%) set no upper age limit and 83 (28%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing doxorubicin in Sarcoma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a confirmed diagnosis of STS for which olaratumab and doxorubicin would be appropriate therapy. Participants with a diagnosis of Grade 1 liposarcoma are eligible if there is histological or radiographic evidence of evolution to more aggressive disease. Participants with Kaposi's sarcoma and gastrointestinal stromal tumors (GIST) will be excluded. Participants must have potentially resectable disease (as assessed by the study investigator) and have a primary tumor lesion deemed amenable to serial .
  • For radiotherapy addendum only: Have a histologically confirmed diagnosis of STS of the extremities, Grade 2 or 3, >5 centimeters, for which olaratumab and radiotherapy would be appropriate therapy. Participants with Kaposi's sarcoma, GIST or myxoid liposarcoma will be excluded.
  • Have consented to undergo mandatory serial peripheral whole blood and tumor tissue sampling.

Exclusion criteria

Exclusion Criteria:

  • Have active central nervous system (CNS) or () at the time of enrollment. Participants with a history of a CNS metastasis previously treated with curative intent (for example, stereotactic radiation or surgery) that have not progressed on follow-up imaging, have been asymptomatic for at least 60 days and are not receiving systemic and or/anticonvulsants, are eligible. Participants with signs or symptoms of neurological compromise should have appropriate radiographic imaging performed before enrollment to rule out brain metastasis.
  • Have received prior treatment with doxorubicin, epirubicin, idarubicin, and/or other anthracyclines or anthracenediones; the participant has received treatment with olaratumab or has participated in a prior olaratumab trial.
  • For radiotherapy addendum only: Have received previous radiotherapy in the primary tumor lesion and/or prior treatment with olaratumab or has participated in a prior olaratumab trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Olaratumab + Doxorubicin

    Cycle 1: Olaratumab 20 milligram per kilogram (mg/kg) given intravenously (IV) on Day 1 and Day 8 (21 day cycle). Cycle 2: Olaratumab 20 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycle). Cycle 3 through Cycle 7: Olaratumab 15 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycles).

    Drug: Olaratumab · Drug: Doxorubicin

  • Experimental
    Olaratumab + Radiotherapy Addendum

    Olaratumab given IV on Day 1 and Day 8 (21 day cycle) concurrently with radiotherapy. Radiotherapy addendum was not implemented.

    Drug: Olaratumab · Radiation: External Beam Radiotherapy

Interventions

  • Administered IV

    Also known as: LY3012207

  • Administered IV

  • RadiationExternal Beam Radiotherapy
06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Enumeration of Circulating Tumor Cells (CTCs) in Whole Blood

    Enumeration of CTCs pre- and post- treatment with olaratumab may be a useful biomarker given the predilection for sarcomas to spread hematogenously.

    Time frame: Baseline, End of Cycle 1 (21 days)

  2. Percent Change From Baseline in Gene Expression of Platelet-Derived Growth Factor Receptor Alpha (PGDFRα) and PGDFR Beta (β) in Tumor Tissue

    Over-activity of PDGF signaling is associated with the development of certain malignant diseases. Olaratumab is an IgG1 antagonist of PDGFRα.

    Time frame: Baseline, End of Cycle 1 (21 days)

  3. Percent Change From Baseline in Gene Expression of PDGF A, PDGF B, PDGF C, and PDGF-D Canonical Ligands in Tumor Tissue

    PDGF A, PDGF B, PDGF C, and PDGF D are platelet-derived growth factor canonical ligands associated with activation of PDGFR α and β.

    Time frame: Baseline, End of Cycle 1 (21 days)

Secondary outcomes

  1. Progression Free Survival (PFS)

    Progression-free survival (PFS) is defined as the time from the date of first study dose to the first date of radiologic disease progression or death due to any cause. Progressive disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression.

    Time frame: Baseline to Objective Progression or Death from Any Cause (Up to 18 Months)

  2. Objective Response Rate (ORR): Percent of Participants With Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR)

    Overall Response Rate (ORR) is defined as the percentage of participants achieving a best overall response of either Complete Response (CR) or Partial Response (PR) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR is defined as a disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \<10 mm and normalization of tumor marker results; PR is defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. The best overall response is the best response from the start of the treatment until progressive disease (PD)/recurrence.

    Time frame: Baseline to Measured Progressive Disease (Up to 18 Months)

  3. Disease Control Rate (DCR): Percent of Participants Who Exhibit Stable Disease (SD), CR or PR

    Disease control rate (DCR) is defined as the percentage of participants achieving a best overall response of CR, PR, or SD as determined by RECIST 1.1. CR is defined as a disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \<10 mm and normalization of tumor marker results; PR is defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters; SD is defined as neither sufficient shrinking to qualify as PR nor sufficient increase to qualify for PD. Participants who do not have any post-baseline tumor response assessments for any reason are considered non-responders and are included in the denominator when calculating the response rate.

    Time frame: Baseline to Measured Progressive Disease (Up to 18 Months)

  4. Percentage of Participants With Resectable Tumors (Resectability Rate)

    Resectability rate is obtained when the total number of participants with resectable tumors is divided by the total number of participants. Resectability of a tumor is determined by the surgeon and multi-disciplinary team and dependent on tumor stage and the participants coexisting medical conditions.

    Time frame: Cycle 1 through Cycle 7 (Up to 6 Months)

  5. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab Monotherapy

    Summary of Cmax of olaratumab monotherapy on Cycle 1 Day 1 and Day 8

    Time frame: Cycle 1 Days 1 and 8: Predose; 5 minutes(m) post-infusion

  6. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab

    Cmax of olaratumab Cycles 2 and 3 Day 1 and 8 of a 21-day cycle.

    Time frame: Cycle 2 Day 1: Predose, 5 minutes(m) post-infusion, 24 hours(h), 96h; Day 8:Predose, 5 m, and 24h, 48h, 96h, and 240h postdose; Cycle 3 Day 1 and Day 8: Predose and 5m post-infusion

  7. Number of Participants With Anti-Olaratumab Antibodies

    A participant is counted as positive if they had at least one anti-olaratumab antibody positive result during the study.

    Time frame: Predose Cycle 1 Day 1 through Follow-Up (Up to 8 Months)

07

Results

Posted Aug 12, 2019
Limitations and caveats
Radiotherapy addendum was not implemented due to business decisions. There were no safety or efficacy issues related to the addendum that contributed to this decision.

Participant flow

Participants are considered to have completed the study if they completed one cycle of monotherapy and all 6 cycles of combination therapy.

Participant flow — Overall Study
MilestoneOlaratumab + Doxorubicin
Started51
Received at least one dose of study drug51
Completed11
Not completed40
Withdrew: Progressive disease23
Withdrew: Surgical resection10
Withdrew: Adverse event4
Withdrew: Physician decision2
Withdrew: Death1

Outcome measures

PrimaryPercent Change From Baseline in Enumeration of Circulating Tumor Cells (CTCs) in Whole Blood

Enumeration of CTCs pre- and post- treatment with olaratumab may be a useful biomarker given the predilection for sarcomas to spread hematogenously.

Time frame:
Baseline, End of Cycle 1 (21 days)
Reported as:
Mean · percent change
Percent Change From Baseline in Enumeration of Circulating Tumor Cells (CTCs) in Whole Blood
percent changeOlaratumab
Traditional CTCs846.93 ± 3260.60
All Population CTCs820.11 ± 3263.41
PrimaryPercent Change From Baseline in Gene Expression of Platelet-Derived Growth Factor Receptor Alpha (PGDFRα) and PGDFR Beta (β) in Tumor Tissue

Over-activity of PDGF signaling is associated with the development of certain malignant diseases. Olaratumab is an IgG1 antagonist of PDGFRα.

Time frame:
Baseline, End of Cycle 1 (21 days)
Reported as:
Mean · percent change in gene expression
Percent Change From Baseline in Gene Expression of Platelet-Derived Growth Factor Receptor Alpha (PGDFRα) and PGDFR Beta (β) in Tumor Tissue
percent change in gene expressionOlaratumab
PDGF Receptor α6162.86 ± 32383.49
PDGF Receptor β1246.25 ± 7024.82
PrimaryPercent Change From Baseline in Gene Expression of PDGF A, PDGF B, PDGF C, and PDGF-D Canonical Ligands in Tumor Tissue

PDGF A, PDGF B, PDGF C, and PDGF D are platelet-derived growth factor canonical ligands associated with activation of PDGFR α and β.

Time frame:
Baseline, End of Cycle 1 (21 days)
Reported as:
Mean · percent change in gene expression
Percent Change From Baseline in Gene Expression of PDGF A, PDGF B, PDGF C, and PDGF-D Canonical Ligands in Tumor Tissue
percent change in gene expressionOlaratumab
Canonical Ligand PDGF - A189.37 ± 672.91
Canonical Ligand PDGF - B602.01 ± 2798.92
Canonical Ligand PDGF - C1107.45 ± 6053.12
Canonical Ligand PDGF - D2630.36 ± 14425.92
SecondaryProgression Free Survival (PFS)

Progression-free survival (PFS) is defined as the time from the date of first study dose to the first date of radiologic disease progression or death due to any cause. Progressive disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression.

Time frame:
Baseline to Objective Progression or Death from Any Cause (Up to 18 Months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsOlaratumab + Doxorubicin
Progression Free Survival (PFS)2.86 (1.41 to 9.72)
SecondaryObjective Response Rate (ORR): Percent of Participants With Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR)

Overall Response Rate (ORR) is defined as the percentage of participants achieving a best overall response of either Complete Response (CR) or Partial Response (PR) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR is defined as a disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \<10 mm and normalization of tumor marker results; PR is defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. The best overall response is the best response from the start of the treatment until progressive disease (PD)/recurrence.

Time frame:
Baseline to Measured Progressive Disease (Up to 18 Months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR): Percent of Participants With Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR)
percentage of participantsOlaratumab + Doxorubicin
Objective Response Rate (ORR): Percent of Participants With Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR)11.8
SecondaryDisease Control Rate (DCR): Percent of Participants Who Exhibit Stable Disease (SD), CR or PR

Disease control rate (DCR) is defined as the percentage of participants achieving a best overall response of CR, PR, or SD as determined by RECIST 1.1. CR is defined as a disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \<10 mm and normalization of tumor marker results; PR is defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters; SD is defined as neither sufficient shrinking to qualify as PR nor sufficient increase to qualify for PD. Participants who do not have any post-baseline tumor response assessments for any reason are considered non-responders and are included in the denominator when calculating the response rate.

Time frame:
Baseline to Measured Progressive Disease (Up to 18 Months)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR): Percent of Participants Who Exhibit Stable Disease (SD), CR or PR
percentage of participantsOlaratumab + Doxorubicin
Disease Control Rate (DCR): Percent of Participants Who Exhibit Stable Disease (SD), CR or PR52.9
SecondaryPercentage of Participants With Resectable Tumors (Resectability Rate)

Resectability rate is obtained when the total number of participants with resectable tumors is divided by the total number of participants. Resectability of a tumor is determined by the surgeon and multi-disciplinary team and dependent on tumor stage and the participants coexisting medical conditions.

Time frame:
Cycle 1 through Cycle 7 (Up to 6 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Resectable Tumors (Resectability Rate)
percentage of participantsOlaratumab + Doxorubicin
Percentage of Participants With Resectable Tumors (Resectability Rate)35.3 (22.4306 to 49.9318)
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab Monotherapy

Summary of Cmax of olaratumab monotherapy on Cycle 1 Day 1 and Day 8

Time frame:
Cycle 1 Days 1 and 8: Predose; 5 minutes(m) post-infusion
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab Monotherapy
micrograms per milliliter (µg/mL)Olaratumab
Cycle 1 Day 1510 ± 22
Cycle 1 Day 8661 ± 24
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab

Cmax of olaratumab Cycles 2 and 3 Day 1 and 8 of a 21-day cycle.

Time frame:
Cycle 2 Day 1: Predose, 5 minutes(m) post-infusion, 24 hours(h), 96h; Day 8:Predose, 5 m, and 24h, 48h, 96h, and 240h postdose; Cycle 3 Day 1 and Day 8: Predose and 5m post-infusion
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab
micrograms per milliliter (µg/mL)Olaratumab + Doxorubicin
Cycle 2 Day 1624 ± 26
Cycle 2 Day 8711 ± 28
Cycle 3 Day 1521 ± 30
Cycle 3 Day 8601 ± 32
SecondaryNumber of Participants With Anti-Olaratumab Antibodies

A participant is counted as positive if they had at least one anti-olaratumab antibody positive result during the study.

Time frame:
Predose Cycle 1 Day 1 through Follow-Up (Up to 8 Months)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Olaratumab Antibodies
ParticipantsOlaratumab + Doxorubicin
Number of Participants With Anti-Olaratumab Antibodies1

Adverse events

Collected over Baseline to end of study (Up to 46 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaratumab + Doxorubicin3/51 (5.9%)22/51 (43.1%)50/51 (98%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventOlaratumab + Doxorubicin
Febrile neutropeniaBlood and lymphatic system disorders9/51
SepsisInfections and infestations2/51
AnaemiaBlood and lymphatic system disorders1/51
Atrial fibrillationCardiac disorders1/51
Cardiopulmonary failureCardiac disorders1/51
DiarrhoeaGastrointestinal disorders1/51
Gastrointestinal obstructionGastrointestinal disorders1/51
Intestinal perforationGastrointestinal disorders1/51
StomatitisGastrointestinal disorders1/51
PyrexiaGeneral disorders1/51
Most frequent other events
Showing 10 of 42
Most frequent other events
EventOlaratumab + Doxorubicin
NauseaGastrointestinal disorders27/51
FatigueGeneral disorders24/51
StomatitisGastrointestinal disorders22/51
ConstipationGastrointestinal disorders20/51
Decreased appetiteMetabolism and nutrition disorders17/51
AlopeciaSkin and subcutaneous tissue disorders16/51
AstheniaGeneral disorders13/51
DiarrhoeaGastrointestinal disorders12/51
VomitingGastrointestinal disorders12/51
AnaemiaBlood and lymphatic system disorders11/51

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)Olaratumab + Doxorubicin
<=18 years0
Between 18 and 65 years37
>=65 years14
Sex: Female, Male
Sex: Female, Male(Participants)Olaratumab + Doxorubicin
Female24
Male27
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Olaratumab + Doxorubicin
Hispanic or Latino4
Not Hispanic or Latino44
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Olaratumab + Doxorubicin
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American2
White47
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Olaratumab + Doxorubicin
United States17
Italy3
United Kingdom4
France2
Spain25
Circulating Tumor Cells (CTC)
Circulating Tumor Cells (CTC)(CTC per milliliter)Olaratumab + Doxorubicin
Traditional CTC2.183 ± 2.631
All Population CTC2.446 ± 2.797
Platelet-Derived Growth Factor Receptor Alpha (PGDFRα ) and PGDFR Beta (β)
Platelet-Derived Growth Factor Receptor Alpha (PGDFRα ) and PGDFR Beta (β)(relative gene expression units)Olaratumab + Doxorubicin
PGDFRα301.68 ± 570.79
PGDFRβ812.49 ± 1260.23
PDGF Canonical Ligands -A, -B, -C, -D
PDGF Canonical Ligands -A, -B, -C, -D(relative gene expression units)Olaratumab + Doxorubicin
PGDF-A12.90 ± 18.46
PDGF-B230.62 ± 1151.87
PDGF-C227.68 ± 447.56
PDGF-D33.22 ± 69.99
08

Study locations

14 sites
  • USC/Norris Comp Cancer Center
    Los Angeles, California 90033, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • All Children's Hospital
    Saint Petersburg, Florida 33701, United States
  • Moffitt Cancer Center & Research Inst
    Tampa, Florida 33612, United States
  • Kansas City Cancer Center
    Overland Park, Kansas 66210, United States
  • Washington University Medical Center
    Saint Louis, Missouri 63110, United States
  • Levine Children's Hospital
    Charlotte, North Carolina 28203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon, 69373, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20133, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08025, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41013, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, SW3 6JJ, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Jul 2018, 20 months.

Results were first posted in Aug 2019, 1 year 1 month after primary completion.

Of 72 industry-sponsored phase 1 interventional studies under Sarcoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 66. This study's 20 months is below that.

Counting every sponsor, half of 161 studies reached it within 56 months; a quarter within 35 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2016
First posted
May 26, 2016
StartActual
Oct 11, 2016
Primary completionActual
Jul 5, 2018
CompletionActual
Jul 5, 2018
Results first posted
Aug 12, 2019
Last update
Aug 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02783599
Responsible party
Sponsor
First posted
May 26, 2016
Start date
Oct 11, 2016
Primary completion
Jul 5, 2018
Completion
Jul 5, 2018
Results posted
Aug 12, 2019
Last update
Aug 12, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxorubicin

Start the discussion